Drug intelligence / Profile preview

Sarocladium strictum

Development stage
Unknown
Modality
Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Intradermal, Subcutaneous, Percutaneous
01

Overview

Sarocladium strictum is a filamentous fungus with diverse biological activities and applications. It is recognized as an opportunistic pathogen, capable of causing rare but severe central nervous system infections, such as meningoencephalitis, particularly in immunocompromised individuals. Beyond its pathogenic role, *S. strictum* is a significant source of various bioactive compounds and enzymes with potential therapeutic, industrial, and agricultural uses. These include l-asparaginase, an enzyme with anti-cancerous properties due to its ability to deplete L-asparagine, and 6-O-α-rhamnosyl-β-glucosidase (αRβG), which can synthesize rutinoside-derivatives with enhanced anti-tumoral activity against pancreatic cancer cells. The fungus also produces gluco-oligosaccharide oxidase (GOOX), utilized in enzymatic pathways for the production of chemicals like 4-O-methylglucaric acid and in high-throughput assays. In agricultural contexts, *S. strictum* produces extracellular polymeric substances (EPS) that act as biostimulants, enhancing plant immune responses and promoting growth in crops like wheat. Environmentally, it plays a role in bioremediation, demonstrating synergistic activity with bacteria in degrading LDPE microplastics, and acts as a natural entomopathogenic agent against invasive insects like the spotted lanternfly. A protease complex from *S. strictum* has also been studied for its thrombolytic potential.

Other names
Acremonium strictum
02

Targets

F (Coagulation factors)

Beyond the preview

Go deeper on Sarocladium strictum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sarocladium strictum.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call